ARCHIVES

Also FDA clarifies data requirements for phase I IND applications.

This article is from The Cancer Letter archive.

Vol. 31 No. 17 | April 29, 2005

Download PDF Visit The Full Archive

Related Articles

ACS Supports NCI’s Bypass Budget In Resolution

March 20, 1992

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

February 7, 2014

McKesson To Purchase US Oncology

November 5, 2010

White House Group Calls For Improved Action Against Carcinogens

September 28, 1979

Clinical Study Section’s Workload Up 50 Percent, Evidence That More Investigators Submitting R01s

January 17, 1992

Breast Cancer Task Force Must Take More Active Role In RFP Development, New Chairman Insists

November 14, 1975